Private Capital Advisors Inc. increased its stake in shares of ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) by 294.1% in the 4th quarter, HoldingsChannel reports. The firm owned 39,397 shares of the exchange traded fund’s stock after purchasing an additional 29,401 shares during the period. Private Capital Advisors Inc.’s holdings in ProShares Ultra Nasdaq Biotechnology ETF were worth $2,209,000 as of its most recent SEC filing.

ProShares Ultra Nasdaq Biotechnology ETF (BIB) traded up $0.81 on Friday, reaching $61.54. The company had a trading volume of 238,797 shares, compared to its average volume of 254,689. ProShares Ultra Nasdaq Biotechnology ETF has a 1 year low of $40.22 and a 1 year high of $64.51.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.watchlistnews.com/private-capital-advisors-inc-has-2-21-million-position-in-proshares-ultra-nasdaq-biotechnology-etf-bib/1804823.html.

ProShares Ultra Nasdaq Biotechnology ETF Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.

Want to see what other hedge funds are holding BIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB).

Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.